BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21803612)

  • 1. Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy.
    Saini A; Berruti A; Cracco C; Sguazzotti E; Porpiglia F; Russo L; Bertaglia V; Picci RL; Negro M; Tosco A; Campagna S; Scarpa RM; Dogliotti L; Furlan PM; Ostacoli L
    Urol Oncol; 2013 Apr; 31(3):352-8. PubMed ID: 21803612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Hammett J; Malcolm JB; Judge BA; Womack JH; Kincade MC; Ogles ML; Mancini JG; Patterson AL; Wake RW; Derweesh IH
    Can J Urol; 2008 Oct; 15(5):4249-56; discussion 4256. PubMed ID: 18814813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
    Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
    BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of sleep in patients receiving androgen deprivation therapy for prostate cancer.
    Koskderelioglu A; Gedizlioglu M; Ceylan Y; Gunlusoy B; Kahyaoglu N
    Neurol Sci; 2017 Aug; 38(8):1445-1451. PubMed ID: 28484881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
    Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
    Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body image perceptions in men with prostate cancer.
    Harrington JM; Jones EG; Badger T
    Oncol Nurs Forum; 2009 Mar; 36(2):167-72. PubMed ID: 19273405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy.
    Chipperfield K; Fletcher J; Millar J; Brooker J; Smith R; Frydenberg M; Burney S
    Psychooncology; 2013 Oct; 22(10):2169-76. PubMed ID: 23483679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
    Stenmark MH; Blas K; Halverson S; Sandler HM; Feng FY; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e335-44. PubMed ID: 21645976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation therapy for prostate cancer: effects on hand function.
    Soyupek F; Soyupek S; Perk H; Ozorak A
    Urol Oncol; 2008; 26(2):141-6. PubMed ID: 18312932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
    Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy.
    Ost P; Cozzarini C; De Meerleer G; Fiorino C; De Potter B; Briganti A; Nagler EV; Montorsi F; Fonteyne V; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):960-5. PubMed ID: 22172901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Information needs of men on androgen deprivation therapy.
    Soeyonggo T; Warde P; Fleshner N; Timilshina N; Alibhai SM
    BJU Int; 2012 May; 109(10):1503-9. PubMed ID: 21883845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
    Ulloa EW; Salup R; Patterson SG; Jacobsen PB
    Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
    BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
    Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry.
    Sadetsky N; Greene K; Cooperberg MR; Hubbard A; Carroll PR; Satariano W
    Cancer; 2011 Oct; 117(19):4406-13. PubMed ID: 21412760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
    Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.